Growth Metrics

GoodRx Holdings (GDRX) Cost of Revenue (2019 - 2026)

GoodRx Holdings' Cost of Revenue history spans 7 years, with the latest figure at -$195.3 million for Q4 2025.

  • On a quarterly basis, Cost of Revenue fell 159.0% to -$195.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $57.6 million, a 84.31% decrease, with the full-year FY2025 number at $57.6 million, down 84.31% from a year prior.
  • Cost of Revenue hit -$195.3 million in Q4 2025 for GoodRx Holdings, down from $83.5 million in the prior quarter.
  • Over the last five years, Cost of Revenue for GDRX hit a ceiling of $331.1 million in Q4 2024 and a floor of -$195.3 million in Q4 2025.
  • Historically, Cost of Revenue has averaged $57.2 million across 5 years, with a median of $81.6 million in 2021.
  • Biggest five-year swings in Cost of Revenue: soared 1224.04% in 2021 and later tumbled 159.0% in 2025.
  • Tracing GDRX's Cost of Revenue over 5 years: stood at $106.5 million in 2021, then fell by 21.0% to $84.1 million in 2022, then grew by 11.44% to $93.8 million in 2023, then surged by 253.16% to $331.1 million in 2024, then crashed by 159.0% to -$195.3 million in 2025.
  • Business Quant data shows Cost of Revenue for GDRX at -$195.3 million in Q4 2025, $83.5 million in Q3 2025, and $84.9 million in Q2 2025.